Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol><A HREF="https://www2.mfour.med.kyoto-u.ac.jp/en/index.html" target="_blank">Honjo Lab HP</A> 開発年:2002年 開発者:本庶佑先生、岡崎一美先生 機関名:京都大学大学院医学研究科・分子生物学 Kyoto Univ. 本庶 佑 Immunology and Inflammation Research RBRC00892 Backcross to C57BL/6 (Hemizygote x C57BL/6CrSlc) C(3〜6か月) C (3-6 months) 条件を付加する。<br>1. 公表を前提とした学術研究に限る。<br>2. 研究成果の公表にあたって寄託者への謝辞の表明並びに寄託者の指定する文献を引用する。Proc. Natl. Acad. Sci. USA, 103, 2752-2757 (2006).<br>3. 本件リソースの改変体又は本件リソースの生産方法若しくは使用方法に係る特許を出願した場合、その旨を速やかに寄託者に通知する。 1) The RECIPIENT shall use the BIOLOGICAL RESOURCE only for academic research for the purpose of publishing the research results.<br>2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR and a citation of the following literature(s) designated by the DEPOSITOR are requested. Proc. Natl. Acad. Sci. USA, 103, 2752-2757 (2006).<br>3) RECIPIENT shall notify the PROVIDER upon filing a patent application claiming modification of the BIOLOGICAL RESOURCE or method(s) of manufacture or use(s) of the BIOLOGICAL RESOURCE. C57BL/6-Tg(CAG-EGFP,-Aicda)20Hon/HonRbrc 開発年:2002年開発者:本庶佑先生、岡崎一美先生機関名:京都大学大学院医学研究科・分子生物学 Tasuku HONJO AID-conditional Transgenic mouse line 20 AID-conditional Transgenic mouse line 20 Developed by Drs. Tasuku Honjo and Ilmi Okazaki at Kyoto University in 2002. These transgenic mice constitutively express GFP under control of CAG promoter. When crossed with a Cre recombinase-expressing strain, GFP expression is replaced with mouse AID expression in tissue expressing Cre. AID, Activation-Induced cytidine Deaminase is a molecule which specifically expressed in B lymphocytes after antigen stimulation, playing a central role in acquisition for B cell of antibody gene variety. C57BL/6 マウスと交配し、系統維持している。 <a href='https://brc.riken.jp/mus/pcr00892'>Genotyping protocol -PCR-</a> Cre transgenic mouseと交配することにより mAIDをconditionalに発現させることができる。Creの発現がない条件ではマーカーとしてGFPが発現する。簡便には末梢血のFACSによるGFPの検出でよい。 Cre/loxP system CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), phage P1 loxP sites, Jellyfish GFP cDNA, mouse Aicda cDNA Fluorescent Proteins/lacZ System 京都大学 AID-conditional Transgenic mouse line 20 true